Connect with us

Health

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward – TCTMD

DREAM-HF provides hints of an anti-inflammatory effect and benefits beyond the heart, setting up future trials.

Published

on

Article feature image

Targeted injection of mesenchymal precursor cells (MPCs) into the myocardium is safe but does not reduce recurrent nonfatal decompensated heart failure (HF) events in patients with chronic HF with reduced ejection fraction (HFrEF), the randomized DREAM-HF…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending